Imugene
Imugene is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment. Their pipeline includes B-cell immunotherapies and oncolytic virotherapy technologies designed to activate the immune system against cancer cells. Imugene aims to improve the lives of cancer patients by creating more effective and tolerable treatments.
Short position
Imugene (ASX:IMU) has 0.34% of its shares on issue reported as short positions as of 5 Oct 2026, or about 1,858,764 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 0.30 percentage points. Its highest recorded short interest was 8.10% in August 2023. IMU is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Imugene (IMU) short interest history
IMU Short Interest History
- 30-day change
- -0.02pp
- 90-day change
- -0.30pp
- 1-year change
- -1.44pp
- All-time high
- 8.10% (August 2023)
- All-time low
- 0.00% (July 2018)
Is IMU heavily shorted?
Not especially: 0.34% short interest is modest by ASX standards, ranking #362 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has IMU's short interest changed recently?
Over the past 30 days Imugene's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.34% of shares on issue.
What is the highest IMU's short interest has been?
Since 2017, Imugene's short interest peaked at 8.10% in August 2023 and bottomed at 0.00% in July 2018.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2017. See our methodology.